Working to Eradicate Gynecologic Cancers

Shohreh Shahabi, MD

Chairman
Western Connecticut Health Network/Danbury Hospital
Dept. of OB/GYN
24 Hospital Avenue
Danbury, CT
USA 06810


Biographical Sketch:
I have a broad background in gynecologic oncology, specifically ovarian cancer, representing the key research area. As a postdoctoral fellow at Yale and Albert Einstein, I carried out basic and translational research in gynecologic cancer. While serving as the Director of Gynecologic Oncology Division at Montefiore Medical Center, I established the first basic/translational laboratory in Ovarian Cancer. Professor Susan B. Horwitz served as my mentor and I continue to collaborate closely with her. My research led to the discovery of beta V tubulin as a marker of resistance to Taxol in human ovarian cells. Besides the extensive clinical work and establishment of the division of gynecology oncology, I concomitantly was able to advance my research. Multiple major manuscripts on basic research have been submitted and accepted for publication. I was elected as the Chairman of the Department of Obstetrics and Gynecology at Danbury Hospital in October 2009 and was an integral part of the establishment of the Danbury Hospital Research Institute. I have functioned as primary investigator or co-investigator in multiple research projects at Albert Einstein College of Medicine and currently as Chairman of the Reproductive Tumor Biology Laboratory within the Danbury Hospital Research Institute. As a physician scientist, I have the ability to facilitate the translation of discoveries generated through basic scientific inquiry to targeted therapies for patients. The strong and established research team is expert in the field of tubulin, cytoskeleton and drug resistance research. Our investigations are focused on functional proteomics and finding the new pathways of the drug resistance in regard to microtubule stabilizing agents in the field of gynecologic cancer.

Papers:
235 - Poster Session A HGF/c-Met axis drives cancer aggressiveness in the neoadjuvant setting of ovarian cancer